The Burden of Suboptimal Insulin Dosing in People with Diabetes in Spain: Barriers and Solutions from the Physician Perspective
Virginia Bellido,Natalia Duque,Rachel Newson,Esther Artime,Erik Spaepen,Miriam Rubio de Santos,Jennifer Redondo-Antón,Silvia Díaz-Cerezo,Jorge Navarro
DOI: https://doi.org/10.2147/ppa.s439814
2024-01-17
Patient Preference and Adherence
Abstract:Virginia Bellido, 1 Natalia Duque, 2 Rachel S Newson, 3 Esther Artime, 2 Erik Spaepen, 4 Miriam Rubio de Santos, 2 Jennifer Redondo-Antón, 2 Silvia Díaz-Cerezo, 2 Jorge Navarro 5 1 Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, Spain; 2 Medical Department, Medical Affairs, Eli Lilly and Company, Madrid, Spain; 3 NAPAC Real World Evidence, Medical Affairs, Eli Lilly and Company, Sydney, NSW, Australia; 4 Statistics, HaaPACS GmbH, Schriesheim, Germany; 5 Department of Medicine, University of Valencia, Valencia, Spain Correspondence: Natalia Duque, Eli Lilly and Company, Alcobendas, Madrid, Spain, Email Background: This study aimed to determine physicians' perceptions of the extent of suboptimal insulin dosing and the barriers and solutions to optimal dosing in people with diabetes (PwD) treated with insulin. Methods: A cross-sectional online survey was conducted in four countries with primary care physicians and endocrinologists treating PwD using insulin pens, which included 53 questions on physicians' characteristics and their perceptions of the behaviors of PwD in relation to insulin dosing routines, unmet needs and potential solutions. Analyses were descriptive. Results: Of the 160 physicians (80 primary care physicians, 80 specialists) surveyed in Spain, 58.1% were male and 88.8% had been qualified to practice for more than five years. Most physicians (> 65%) indicated that 0– 30% of PwD missed or skipped, mistimed, or miscalculated an insulin dose in the last 30 days. Common reasons for these actions were that PwD forgot, were out of their normal routine, were too busy or distracted, or were unsure of how much insulin to take. To optimize insulin dosing, over 75% of physicians considered it very helpful for PwD to have real-time insulin dosing calculation guidance, mobile app reminders, a device automatically recording glucose measurements and/or insulin, having insulin and glucose data in one place, and having the time for more meaningful conversations about insulin dosing routines. Conclusion: According to physicians' perspectives, suboptimal insulin dosing remains common among PwD. This survey highlights the need for integrated and automated insulin dosing support to manage the complexity of insulin treatment, improve communications between PwD and physicians, and ultimately improve outcomes for PwD. Plain Language Summary: In Spain, more than 50% of people with diabetes (PwD) do not reach glycemic targets (glycated hemoglobin [HbA1C] under 7%). While there are many innovations in insulin therapy and device technology, treatment adherence is often poor. This study presents results from an online survey of physicians' perceptions of insulin dosing and the barriers and solutions to optimal insulin dosing in Spain. Most physicians indicated that PwD missed or skipped, mistimed, or miscalculated an insulin dose. Common reasons included PwD being out of their normal routine, being too busy or distracted, or being unsure of how much insulin to take. To improve insulin dosing, physicians suggested real-time insulin dosing calculation guidance, mobile app reminders, and a device that automatically records glucose measurements and insulin. Furthermore, having time for more meaningful conversations about insulin dosing routines was found as a solution to improve insulin dosing.There is a need for integrated and automated insulin dosing support to manage insulin treatment, improve communications between PwD and physicians, and improve outcomes for PwD. Keywords: diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, insulin dosing, physicians, Spain, barriers, solutions Diabetes is a severe chronic condition and is becoming a leading cause of blindness, renal failure, lower limb amputation, and cardiovascular disease. 1 In 2021, the worldwide prevalence of diabetes was approximately 10.5% among adults aged 20 to 79 years, and this is estimated to increase to 12.2% by 2045. 2 In Spain, prevalence rates are estimated to range between 10% and 15%. 3 For type 1 diabetes mellitus (T1DM) the current approach for keeping blood glucose levels in a near-normal range is imitating normal insulin secretion with either continuous subcutaneous insulin infusions or multiple doses of insulin. 4 Although early treatment in most individuals with type 2 diabetes mellitus (T2DM) is an oral hypoglycemic agent, the progression to insulin is common. 5 The achievement and maintenance of glycemic control is important to reduce the risk of diabetes-related -Abstract Truncated-
medicine, general & internal